Alfredo G Torres

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/693680/publications.pdf

Version: 2024-02-01

160 papers	9,230 citations	50276 46 h-index	46799 89 g-index
170 all docs	170 docs citations	170 times ranked	7852 citing authors

#	Article	IF	Citations
1	Bacteriaâ€“host communication: The language of hormones. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 8951-8956.	7.1	776
2	Quorum sensingEscherichia coliregulators B and C (QseBC): a novel two-component regulatory system involved in the regulation of flagella and motility by quorum sensing inE. coli. Molecular Microbiology, 2002, 43, 809-821.	2.5	457
3	Melioidosis. Nature Reviews Disease Primers, 2018, 4, 17107.	30.5	430
4	Quorum Sensing Is a Global Regulatory Mechanism in Enterohemorrhagic Escherichia coli O157:H7. Journal of Bacteriology, 2001, 183, 5187-5197.	2.2	389
5	The flagella of enteropathogenic Escherichia coli mediate adherence to epithelial cells. Molecular Microbiology, 2002, 44, 361-379.	2.5	334
6	TonB-Dependent Systems of Uropathogenic Escherichia coli : Aerobactin and Heme Transport and TonB Are Required for Virulence in the Mouse. Infection and Immunity, 2001, 69, 6179-6185.	2.2	267
7	Haem ironâ€transport system in enterohaemorrhagic Escherichia coli O157:H7. Molecular Microbiology, 1997, 23, 825-833.	2.5	230
8	Adherence of Diarrheagenic Escherichia coli Strains to Epithelial Cells. Infection and Immunity, 2005, 73, 18-29.	2.2	195
9	Genome sequence of adherent-invasive Escherichia coli and comparative genomic analysis with other E. coli pathotypes. BMC Genomics, 2010, 11, 667.	2.8	193
10	Identification and Characterization of lpfABCC â€² DE , a Fimbrial Operon of Enterohemorrhagic Escherichia coli O157:H7. Infection and Immunity, 2002, 70, 5416-5427.	2.2	173
11	Escherichia coli isolated from a Crohn's disease patient adheres, invades, and induces inflammatory responses in polarized intestinal epithelial cells. International Journal of Medical Microbiology, 2008, 298, 397-409.	3.6	163
12	Multiple Elements Controlling Adherence of Enterohemorrhagic Escherichia coli O157:H7 to HeLa Cells. Infection and Immunity, 2003, 71, 4985-4995.	2.2	160
13	StcE, a metalloprotease secreted by Escherichia coli O157:H7, specifically cleaves C1 esterase inhibitor. Molecular Microbiology, 2002, 45, 277-288.	2.5	158
14	Glanders: off to the races withBurkholderia mallei. FEMS Microbiology Letters, 2007, 277, 115-122.	1.8	149
15	Enteropathogenic Escherichia coli: foe or innocent bystander?. Clinical Microbiology and Infection, 2015, 21, 729-734.	6.0	147
16	Molecular Mechanisms That Mediate Colonization of Shiga Toxin-Producing Escherichia coli Strains. Infection and Immunity, 2012, 80, 903-913.	2.2	141
17	Structure of the Shigella dysenteriae haem transport locus and its phylogenetic distribution in enteric bacteria. Molecular Microbiology, 1998, 28, 1139-1152.	2.5	137
18	The two-component system QseEF and the membrane protein QseG link adrenergic and stress sensing to bacterial pathogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 5889-5894.	7.1	137

#	Article	IF	Citations
19	The aerobactin iron transport system genes in Shigella flexneri are present within a pathogenicity island. Molecular Microbiology, 1999, 33, 63-73.	2.5	135
20	A Novel Two-Component Signaling System That Activates Transcription of an Enterohemorrhagic Escherichia coli Effector Involved in Remodeling of Host Actin. Journal of Bacteriology, 2007, 189, 2468-2476.	2.2	127
21	Flagellin of Enteropathogenic Escherichia coli Stimulates Interleukin-8 Production in T84 Cells. Infection and Immunity, 2003, 71, 2120-2129.	2.2	125
22	Enterohemorrhagic Escherichia coli Adhesins. Microbiology Spectrum, 2014, 2, EHEC00032013.	3.0	109
23	Differential Binding of Escherichia coli O157:H7 to Alfalfa, Human Epithelial Cells, and Plastic Is Mediated by a Variety of Surface Structures. Applied and Environmental Microbiology, 2005, 71, 8008-8015.	3.1	103
24	Characterization of Cah, a calcium-binding and heat-extractable autotransporter protein of enterohaemorrhagic Escherichia coli. Molecular Microbiology, 2002, 45, 951-966.	2.5	100
25	Extensive Identification of Bacterial Riboflavin Transporters and Their Distribution across Bacterial Species. PLoS ONE, 2015, 10, e0126124.	2.5	98
26	Characterization of the second long polar (LP) fimbriae of O157:H7 and distribution of LP fimbriae in other pathogenic strains. FEMS Microbiology Letters, 2004, 238, 333-344.	1.8	93
27	Long Polar Fimbriae Contribute to Colonization by Escherichia coli O157:H7 In Vivo. Infection and Immunity, 2004, 72, 6168-6171.	2.2	92
28	Polysaccharides Cellulose, Poly-Î²-1,6- N -Acetyl- <scp>d</scp> -Glucosamine, and Colanic Acid Are Required for Optimal Binding of Escherichia coli O157:H7 Strains to Alfalfa Sprouts and K-12 Strains to Plastic but Not for Binding to Epithelial Cells. Applied and Environmental Microbiology, 2008, 74, 2384-2390.	3.1	92
29	Present and future therapeutic strategies for melioidosis and glanders. Expert Review of Anti-Infective Therapy, 2010, 8, 325-338.	4.4	91
30	Cloning, Expression, and Characterization of Fimbrial Operon F9 from Enterohemorrhagic Escherichia coli O157:H7. Infection and Immunity, 2006, 74, 2233-2244.	2.2	89
31	A Burkholderia pseudomallei Outer Membrane Vesicle Vaccine Provides Protection against Lethal Sepsis. Vaccine Journal, 2014, 21, 747-754.	3.1	85
32	Role of Shiga toxin versus H7 flagellin in enterohaemorrhagic Escherichia coli signalling of human colon epithelium in vivo. Cellular Microbiology, 2006, 8, 869-879.	2.1	82
33	A gold nanoparticle-linked glycoconjugate vaccine against Burkholderia mallei. Nanomedicine: Nanotechnology, Biology, and Medicine, 2015, 11, 447-456.	3.3	79
34	Recent advances in adherence and invasion of pathogenic Escherichia coli. Current Opinion in Infectious Diseases, 2014, 27, 459-464.	3.1	78
35	Characterization of the second long polar (LP) fimbriae ofEscherichia coliO157:H7 and distribution of LP fimbriae in other pathogenicE. colistrains. FEMS Microbiology Letters, 2004, 238, 333-344.	1.8	75
36	Host S-nitrosylation inhibits clostridial small moleculeâ€“activated glucosylating toxins. Nature Medicine, 2011, 17, 1136-1141.	30.7	75

#	Article	IF	Citations
37	The IbeA Invasin of Adherent-Invasive Escherichia coli Mediates Interaction with Intestinal Epithelia and Macrophages. Infection and Immunity, 2015, 83, 1904-1918.	2.2	65
38	Outer Membrane Protein A of Escherichia coli O157:H7 Stimulates Dendritic Cell Activation. Infection and Immunity, 2006, 74, 2676-2685.	2.2	64
39	Long Polar Fimbriae of Enterohemorrhagic Escherichia coli O157:H7 Bind to Extracellular Matrix Proteins. Infection and Immunity, 2011, 79, 3744-3750.	2.2	63
40	Synthesis and in vitro Efficacy Studies of Silver Carbene Complexes on Biosafety Level 3 Bacteria. European Journal of Inorganic Chemistry, 2009, 2009, 1739-1745.	2.0	61
41	Ler and H-NS, Regulators Controlling Expression of the Long Polar Fimbriae of Escherichia coli O157:H7. Journal of Bacteriology, 2007, 189, 5916-5928.	2.2	59
42	Protection of non-human primates against glanders with a gold nanoparticle glycoconjugate vaccine. Vaccine, 2015, 33, 686-692.	3.8	59
43	Consensus on the Development of Vaccines against Naturally Acquired Melioidosis. Emerging Infectious Diseases, 2015, 21, .	4.3	57
44	Development of Subunit Vaccines That Provide High-Level Protection and Sterilizing Immunity against Acute Inhalational Melioidosis. Infection and Immunity, 2018, 86, .	2.2	55
45	Environmental regulation and colonization attributes of the long polar fimbriae (LPF) of Escherichia coli O157:H7. International Journal of Medical Microbiology, 2007, 297, 177-185.	3.6	54
46	TolC and DsbA are needed for the secretion of STB, a heat-stable enterotoxin ofEscherichia coli. Molecular Microbiology, 1995, 18, 237-245.	2.5	53
47	Molecular Epidemiology of the Iron Utilization Genes of Enteroaggregative Escherichia coli. Journal of Clinical Microbiology, 2004, 42, 36-44.	3.9	53
48	A Double, Long Polar Fimbria Mutant of Escherichia coli O157:H7 Expresses Curli and Exhibits Reduced In Vivo Colonization. Infection and Immunity, 2012, 80, 914-920.	2.2	50
49	Hacking the host: exploitation of macrophage polarization by intracellular bacterial pathogens. Pathogens and Disease, 2020, 78, .	2.0	50
50	Genes Related to Long Polar Fimbriae of Pathogenic Escherichia coli Strains as Reliable Markers To Identify Virulent Isolates. Journal of Clinical Microbiology, 2009, 47, 2442-2451.	3.9	48
51	Advances in the development of enterohemorrhagic Escherichia coli vaccines using murine models of infection. Vaccine, 2013, 31, 3229-3235.	3.8	46
52	Use of Reverse Vaccinology in the Design and Construction of Nanoglycoconjugate Vaccines against Burkholderia pseudomallei. Vaccine Journal, 2017, 24, .	3.1	46
53	The effects of lowâ€shear stress on Adherentâ€invasive Escherichia coli. Environmental Microbiology, 2008, 10, 1512-1525.	3.8	44
54	TonB Is Required for Intracellular Growth and Virulence of Shigella dysenteriae. Infection and Immunity, 2000, 68, 6329-6336.	2.2	43

#	Article	IF	Citations
55	Long polar fimbriae and tissue tropism in Escherichia coli O157:H7. Microbes and Infection, 2006, 8, 1741-1749.	1.9	43
56	Comparative Burkholderia pseudomallei natural history virulence studies using an aerosol murine model of infection. Scientific Reports, 2014, 4, 4305.	3.3	43
57	Identification of Coli Surface Antigen 23, a Novel Adhesin of Enterotoxigenic Escherichia coli. Infection and Immunity, 2012, 80, 2791-2801.	2.2	42
58	Development of a Gold Nanoparticle Vaccine against Enterohemorrhagic Escherichia coli O157:H7. MBio, 2019, 10, .	4.1	42
59	Polysaccharide Specific Monoclonal Antibodies Provide Passive Protection against Intranasal Challenge with Burkholderia pseudomallei. PLoS ONE, 2012, 7, e35386.	2.5	42
60	Recent Advances in Burkholderia mallei and B. pseudomallei Research. Current Tropical Medicine Reports, 2015, 2, 62-69.	3.7	41
61	Recent Advances in Shiga Toxin-Producing Escherichia coli Research in Latin America. Microorganisms, 2018, 6, 100.	3.6	41
62	Burkholderia pseudomallei Î” tonB Î” hcp1 Live Attenuated Vaccine Strain Elicits Full Protective Immunity against Aerosolized Melioidosis Infection. MSphere, 2019, 4, .	2.9	41
63	Identification and Characterization of the Locus for Diffuse Adherence, Which Encodes a Novel Afimbrial Adhesin Found in Atypical Enteropathogenic Escherichia coli. Infection and Immunity, 2005, 73, 4753-4765.	2.2	40
64	Development of a Multiplex PCR Assay for Detection of Shiga Toxin-Producing Escherichia coli, Enterohemorrhagic E. coli, and Enteropathogenic E. coli Strains. Frontiers in Cellular and Infection Microbiology, 2012, 2, 8.	3.9	39
65	SARS-CoV-2: Evolution and Emergence of New Viral Variants. Viruses, 2022, 14, 653.	3.3	39
66	Protective response to subunit vaccination against intranasal Burkholderia mallei and B. pseudomallei challenge. Procedia in Vaccinology, 2010, 2, 73-77.	0.4	38
67	In vivo bioluminescence imaging of Burkholderia mallei respiratory infection and treatment in the mouse model. Frontiers in Microbiology, 2011, 2, 174.	3.5	38
68	Fimbriation and curliation in Escherichia coli O157. Gut Microbes, 2012, 3, 272-276.	9.8	37
69	Characterization of the Burkholderia mallei tonB Mutant and Its Potential as a Backbone Strain for Vaccine Development. PLoS Neglected Tropical Diseases, 2015, 9, e0003863.	3.0	36
70	Pathoadaptive Mutation That Mediates Adherence of Shiga Toxin-Producing Escherichia coli O111. Infection and Immunity, 2005, 73, 4766-4776.	2.2	34
71	Identification and Characterization of RibN, a Novel Family of Riboflavin Transporters from Rhizobium leguminosarum and Other Proteobacteria. Journal of Bacteriology, 2013, 195, 4611-4619.	2.2	33
72	The art of persistenceâ€"the secrets toBurkholderiachronic infections. Pathogens and Disease, 2016, 74, ftw070.	2.0	33

#	Article	IF	Citations
73	Contribution of the Ler- and H-NS-Regulated Long Polar Fimbriae of Escherichia coli O157:H7 during Binding to Tissue-Cultured Cells. Infection and Immunity, 2008, 76, 5062-5071.	2.2	32
74	Escherichia coli diseases in Latin Americaâ€"a â€˜One Healthâ€™ multidisciplinary approach. Pathogens and Disease, 2017, 75, .	2.0	32
75	Melioidosis in Mexico, Central America, and the Caribbean. Tropical Medicine and Infectious Disease, 2018, 3, 24.	2.3	31
76	Burkholderia mallei cellular interactions in a respiratory cell model. Journal of Medical Microbiology, 2009, 58, 554-562.	1.8	30
77	Immunomodulation for gastrointestinal infections. Expert Review of Anti-Infective Therapy, 2012, 10, 391-400.	4.4	30
78	Comparative Genomics and Immunoinformatics Approach for the Identification of Vaccine Candidates for Enterohemorrhagic Escherichia coli O157:H7. Infection and Immunity, 2014, 82, 2016-2026.	2.2	30
79	The Role of Long Polar Fimbriae in Escherichia coli O104:H4 Adhesion and Colonization. PLoS ONE, 2015, 10, e0141845.	2.5	30
80	CadA Negatively Regulates Escherichia coli O157:H7 Adherence and Intestinal Colonization. Infection and Immunity, 2008, 76, 5072-5081.	2.2	29
81	Evaluating New Compounds to Treat Burkholderia pseudomallei Infections. Frontiers in Cellular and Infection Microbiology, 2018, 8, 210.	3.9	29
82	The lpf Gene Cluster for Long Polar Fimbriae Is Not Involved in Adherence of Enteropathogenic Escherichia coli or Virulence of Citrobacter rodentium. Infection and Immunity, 2006, 74, 265-272.	2.2	28
83	Clinical Implications of Enteroadherent Escherichia coli. Current Gastroenterology Reports, 2012, 14, 386-394.	2.5	28
84	Novel multi-component vaccine approaches for Burkholderia pseudomallei. Clinical and Experimental Immunology, 2019, 196, 178-188.	2.6	28
85	Burkholderia mallei CLH001 Attenuated Vaccine Strain Is Immunogenic and Protects against Acute Respiratory Glanders. Infection and Immunity, 2016, 84, 2345-2354.	2.2	27
86	The cad locus of Enterobacteriaceae: More than just lysine decarboxylation. Anaerobe, 2009, 15, 1-6.	2.1	26
87	A transcriptome study of the QseEF two-component system and the QseG membrane protein in enterohaemorrhagic Escherichia coli O157â€Š:â€ŠH7. Microbiology (United Kingdom), 2010, 156, 1167-1175.	1.8	26
88	Adhesin-Encoding Genes from Shiga Toxin-Producing Escherichia coli Are More Prevalent in Atypical than in Typical Enteropathogenic E. coli. Journal of Clinical Microbiology, 2011, 49, 3334-3337.	3.9	26
89	Prophylactic Application of CpG Oligonucleotides Augments the Early Host Response and Confers Protection in Acute Melioidosis. PLoS ONE, 2012, 7, e34176.	2.5	25
90	Host immunity in the protective response to vaccination with heat-killed Burkholderia mallei. BMC Immunology, 2008, 9, 55.	2.2	23

#	Article	IF	Citations
91	Regulatory Control of the Escherichia coli O157:H7 lpf1 Operon by H-NS and Ler. Journal of Bacteriology, 2011, 193, 1622-1632.	2.2	23
92	Host-Microbe Communication within the GI Tract. Advances in Experimental Medicine and Biology, 2008, 635, 93-101.	1.6	23
93	Bile salts induce expression of the afimbrial LDA adhesin of atypical enteropathogenic Escherichia coli. Cellular Microbiology, 2007, 9, 1039-1049.	2.1	21
94	Burkholderia cepacia Complex Vaccines: Where Do We Go from here?. Vaccines, 2016, 4, 10.	4.4	20
95	Polysorbates prevent biofilm formation and pathogenesis of Escherichia coli O104:H4. Biofouling, 2016, 32, 1131-1140.	2.2	20
96	Multicomponent gold nano-glycoconjugate as a highly immunogenic and protective platform against Burkholderia mallei. Npj Vaccines, 2020, 5, 82.	6.0	20
97	In vivo bioluminescence imaging of Escherichia coli O104:H4 and role of aerobactin during colonization of a mouse model of infection. BMC Microbiology, 2012, 12, 112.	3.3	19
98	Current aspects of Shigella pathogenesis. Revista Latinoamericana De MicrobiologÃa, 2004, 46, 89-97.	0.1	19
99	Comparison of the in vitro and in vivo susceptibilities of Burkholderia mallei to Ceftazidime and Levofloxacin. BMC Microbiology, 2009, 9, 88.	3.3	18
100	The long polar fimbriae of STEC O157:H7 induce expression of pro-inflammatory markers by intestinal epithelial cells. Veterinary Immunology and Immunopathology, 2013, 152, 126-131.	1.2	18
101	Multicomponent Gold-Linked Glycoconjugate Vaccine Elicits Antigen-Specific Humoral and Mixed T _H 1-T _H 17 Immunity, Correlated with Increased Protection against Burkholderia pseudomallei. MBio, 2021, 12, e0122721.	4.1	18
102	Identification and characterization of â€œpathoadaptive mutationsâ€•of the cadBA operon in several intestinal Escherichia coli. International Journal of Medical Microbiology, 2006, 296, 547-552.	3.6	17
103	Characterization of the universal stress protein F from atypical enteropathogenic Escherichia coli and its prevalence in Enterobacteriaceae. Protein Science, 2016, 25, 2142-2151.	7.6	17
104	Comparative Antimicrobial Activity of Granulysin against Bacterial Biothreat Agents. Open Microbiology Journal, 2009, 3, 92-96.	0.7	17
105	Protective Antigens Against Glanders Identified by Expression Library Immunization. Frontiers in Microbiology, 2011, 2, 227.	3.5	16
106	Evaluation of Burkholderia mallei Î”tonB Î”hcp1 (CLH001) as a live attenuated vaccine in murine models of glanders and melioidosis. PLoS Neglected Tropical Diseases, 2019, 13, e0007578.	3.0	16
107	Comparative genomics of a subset of Adherent/Invasive Escherichia coli strains isolated from individuals without inflammatory bowel disease. Genomics, 2020, 112, 1813-1820.	2.9	16
108	Sero-characterization of lipopolysaccharide from Burkholderia thailandensis. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2008, 102, S58-S60.	1.8	15

#	Article	IF	Citations
109	Construction of a reporter system to study Burkholderia mallei type III secretion and identification of the BopA effector protein function in intracellular survival. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2008, 102, S127-S133.	1.8	15
110	The Escherichia coli O157:H7 cattle immunoproteome includes outer membrane protein A (OmpA), a modulator of adherence to bovine rectoanal junction squamous epithelial (RSE) cells. Proteomics, 2015, 15, 1829-1842.	2.2	15
111	Evaluating the role of Burkholderia pseudomallei K96243 toxins BPSS0390, BPSS0395, and BPSS1584 in persistent infection. Cellular Microbiology, 2019, 21, e13096.	2.1	15
112	Identification of the long polar fimbriae gene variants in the locus of enterocyte effacement-negative Shiga toxin-producing â€ƒEscherichia coliâ€ƒstrains isolated from humans and cattle in Argentina. FEMS Microbiology Letters, 2010, 308, no-no.	1.8	14
113	Outbreak Caused bycad-Negative Shiga Toxinâ€“ProducingEscherichia coliO111, Oklahoma. Foodborne Pathogens and Disease, 2010, 7, 107-109.	1.8	14
114	Multinucleated Giant Cell Formation as a Portal to Chronic Bacterial Infections. Microorganisms, 2020, 8, 1637.	3.6	14
115	Characterization of the Burkholderia cenocepacia TonB Mutant as a Potential Live Attenuated Vaccine. Vaccines, 2017, 5, 33.	4.4	13
116	Testing the Efficacy and Toxicity of Adenylyl Cyclase Inhibitors against Enteric Pathogens Using In Vitro and In Vivo Models of Infection. Infection and Immunity, 2010, 78, 1740-1749.	2.2	12
117	Environmental regulation of the long polar fimbriae 2 of enterohemorrhagicEscherichia coliO157:H7. FEMS Microbiology Letters, 2014, 357, n/a-n/a.	1.8	12
118	From In silico Protein Epitope Density Prediction to Testing Escherichia coli O157:H7 Vaccine Candidates in a Murine Model of Colonization. Frontiers in Cellular and Infection Microbiology, 2016, 6, 94.	3.9	12
119	Antigen-specific antibody and polyfunctional T cells generated by respiratory immunization with protective Burkholderia Î”tonB Î”hcp1 live attenuated vaccines. Npj Vaccines, 2021, 6, 72.	6.0	12
120	Long polar fimbriae participates in the induction of neutrophils transepithelial migration across intestinal cells infected with enterohemorrhagic E. coli O157:H7. Frontiers in Cellular and Infection Microbiology, 2015, 4, 185.	3.9	11
121	Combating the great mimicker: latest progress in the development of Burkholderia pseudomallei vaccines. Expert Review of Vaccines, 2020, 19, 653-660.	4.4	11
122	Burkholderia pseudomallei as an Enteric Pathogen: Identification of Virulence Factors Mediating Gastrointestinal Infection. Infection and Immunity, 2020, 89, .	2.2	11
123	Monitoring Therapeutic Treatments against Burkholderia Infections Using Imaging Techniques. Pathogens, 2013, 2, 383-401.	2.8	10
124	Subtractive hybridization and identification of putative adhesins in a Shiga toxin-producing eae-negative Escherichia coli. Microbiology (United Kingdom), 2008, 154, 3639-3648.	1.8	8
125	Exploiting the power of OMICS approaches to produceE. coliO157 vaccines. Gut Microbes, 2014, 5, 770-774.	9.8	8
126	Emerging role of biologics for the treatment of melioidosis and glanders. Expert Opinion on Biological Therapy, 2019, 19, 1319-1332.	3.1	8

#	Article	IF	Citations
127	Misidentification of Burkholderia pseudomallei and Other Burkholderia Species From Pediatric Infections in Mexico. Open Forum Infectious Diseases, 2019, 6, ofz008.	0.9	8
128	Description of two fatal cases of melioidosis in Mexican children with acute pneumonia: case report. BMC Infectious Diseases, 2021, 21, 204.	2.9	7
129	Melioidosis: where do we stand in the development of an effective vaccine?. Future Microbiology, 2016, 11, 477-480.	2.0	7
130	Development of Melioidosis Subunit Vaccines Using an Enzymatically Inactive Burkholderia pseudomallei AhpC. Infection and Immunity, 2022, 90, .	2.2	7
131	Increased Mortality in Mice following Immunoprophylaxis Therapy with High Dosage of Nicotinamide in Burkholderia Persistent Infections. Infection and Immunity, 2019, 87, .	2.2	6
132	Predicting toxins found in toxinâ€“antitoxin systems with a role in host-induced Burkholderia pseudomallei persistence. Scientific Reports, 2020, 10, 16923.	3.3	6
133	TonB Is Required for Intracellular Growth and Virulence of Shigella dysenteriae. Infection and Immunity, 2000, 68, 6329-6336.	2.2	6
134	Encapsulation of Asparaginase as a Promising Strategy to Improve In Vivo Drug Performance. Pharmaceutics, 2021, 13, 1965.	4.5	6
135	Restrictive Streptomycin Resistance Mutations Decrease the Formation of Attaching and Effacing Lesions in Escherichia coli O157:H7 Strains. Antimicrobial Agents and Chemotherapy, 2013, 57, 4260-4266.	3.2	5
136	Comparing in vitro and in vivo virulence phenotypes of Burkholderia pseudomallei type G strains. PLoS ONE, 2017, 12, e0175983.	2.5	5
137	The Importance of International Collaborations to Advance Research Endeavors. PLoS Pathogens, 2017, 13, e1006047.	4.7	5
138	Optimization of Multivalent Gold Nanoparticle Vaccines Eliciting Humoral and Cellular Immunity in an In Vivo Model of Enterohemorrhagic Escherichia coli O157:H7 Colonization. MSphere, 2022, 7, e0093421.	2.9	5
139	Intestinal Pathogenic Escherichia coli. , 2009, , 1013-1029.		4
140	Molecular Approaches to Bacterial Vaccines. , 2009, , 63-76.		4
141	Development of reagents and assays for the detection of pathogenic Burkholderia species. Faraday Discussions, 2011, 149, 23-36.	3.2	4
142	Recent Progress in Melioidosis and Glanders. Frontiers in Microbiology, 2012, 3, 149.	3.5	4
143	Burkholderia mallei and Glanders. , 2019, , 161-183.		4
144	Genomic Diversity of Burkholderia pseudomallei Isolates, Colombia. Emerging Infectious Diseases, 2021, 27, 655-658.	4.3	4

#	Article	IF	Citations
145	Adhesins of Enteropathogenic Escherichia coli. EcoSal Plus, 2006, 2, .	5.4	3
146	Recent Progress in Shigella and Burkholderia pseudomallei Vaccines. Pathogens, 2021, 10, 1353.	2.8	3
147	Vacunas contra el SARS-CoV-2: Â¿son una realidad para AmÃ©rica Latina?. Biomedica, 2020, 40, 424-426.	0.7	3
148	The long polar fimbriae operon and its flanking regions in bovineEscherichia coliO157:H43 and STEC O136:H12 strains. Pathogens and Disease, 2013, 68, 1-7.	2.0	2
149	Finding Regulators Associated with the Expression of the Long Polar Fimbriae in Enteropathogenic Escherichia coli. Journal of Bacteriology, 2015, 197, 3658-3665.	2.2	2
150	Enterohemorrhagic Escherichia coli Adhesins. , 0, , 131-155.		2
151	The Challenge to Control Emergence of Antibiotic Resistance in Virulent Escherichia coli Isolates in Latin America. Microbiology Spectrum, 2022, 10, .	3.0	2
152	Melioidosis in Mexico: a Coordinated Effort to Educate the Medical Specialists and the Community About an Unknown Disease Endemic in the Country. Current Tropical Medicine Reports, 2019, 6, 116-119.	3.7	1
153	Melioidosis: The hazards of incomplete peer-review. PLoS Neglected Tropical Diseases, 2019, 13, e0007123.	3.0	1
154	Why Do We Need To Diversify the Microbial Sciences?. MSphere, 2021, 6, e0062521.	2.9	1
155	Diversity, Equity, and Inclusion in the Microbial Sciencesâ€"the Texas Perspective. MBio, 2021, 12, e0262021.	4.1	1
156	Escherichia coli-Related Diseases in Latin America Remain in the Spotlight: the Brazilian Efforts to Understand E. coli Pathogenesis. Open Microbiology Journal, 2011, 5, 54-54.	0.7	1
157	Hybrid and potentially pathogenic Escherichia coli strains. , 2013, , 331-359.		0
158	Maternal immunity, a way to confer protection against enteropathogenic Escherichia coli. Jornal De Pediatria (VersÃ£o Em PortuguÃªs), 2017, 93, 548-550.	0.2	0
159	Roles and Specificities of LPS from Highly Pathogenic Burkholderia Species. FASEB Journal, 2012, 26, 991.7.	0.5	0
160	Evaluating the Contribution of the Predicted Toxinâ€"Antitoxin System HigBA to Persistence, Biofilm Formation, and Virulence in Burkholderia pseudomallei. Infection and Immunity, 0, , .	2.2	0